Clinical significance of anaplasia in childhood rhabdomyosarcoma

J Egypt Natl Canc Inst. 2015 Jun;27(2):83-9. doi: 10.1016/j.jnci.2015.03.003. Epub 2015 Apr 23.

Abstract

Background: The presence of anaplastic features has been known to correlate with poor clinical outcome in various pediatric malignancies, including Wilms tumor and medulloblastoma but not in rhabdomyosarcoma.

Aim: Aim was to study the frequency of anaplasia at presentation in childhood rhabdomyosarcoma and its relationship to clinical and pathological characteristics as well as to outcome.

Patients and methods: Anaplasia was retrospectively assessed in 105 consecutive pediatric rhabdomyosarcoma patients who were registered at the Children's Cancer Hospital in Egypt (CCHE) during the period from July 2007 till the end of May 2010.

Results: Anaplasia was diagnosed in 18 patients (17.1%), focal in 10 (9.5%) and diffuse in 8 (7.6%). The distribution of anaplasia was found to be more common in older patients having age⩾10 years. Also it was more likely to occur in the high risk group and in tumors with unfavorable histology (alveolar subtype), and stage IV. The 3-year failure free survival rates for patients with and without anaplasia were 27.8±10.6% and 53.4±5.8%, respectively (p=0.014) and the 3-year overall survival rates were 35.3±11.6% and 61±6%, respectively (p=0.019).

Conclusions: The frequency of anaplasia in pediatric patients with rhabdomyosarcoma in our study was 17.1%. The presence of anaplasia had statistically significant worse clinical outcome.

Keywords: Anaplasia; Prognostic significance; Rhabdomyosarcoma.

MeSH terms

  • Adolescent
  • Age Factors
  • Anaplasia / pathology*
  • Child
  • Child, Preschool
  • Disease Progression
  • Egypt
  • Female
  • Follow-Up Studies
  • Humans
  • Infant
  • Male
  • Neoplasm Grading
  • Neoplasm Metastasis
  • Neoplasm Staging
  • Prognosis
  • Registries
  • Retrospective Studies
  • Rhabdomyosarcoma / diagnosis*
  • Rhabdomyosarcoma / mortality
  • Rhabdomyosarcoma / pathology*
  • Rhabdomyosarcoma / therapy
  • Survival Analysis
  • Treatment Outcome
  • Tumor Burden